Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 4,29 MB, PDF-dokument
IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N-linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 107619 |
| Tidsskrift | iScience |
| Vol/bind | 26 |
| Udgave nummer | 9 |
| Sider (fra-til) | 1-15 |
| ISSN | 2589-0042 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
We thank the Academic Medical Centre of the University of Amsterdam, the Sanquin Blood Supply Foundation, Janssen Vaccines and Prevention B.V. and Radboud University Medical Center (RUMC) & Bavarian Nordic A/S. We furthermore thank all cohort participants, to whom we are greatly indebted for their extensive participation. Funding: Landsteiner foundation for Blood Transfusion Research (LSBR) grants 1721 and 1908 (G.V.). ZonMW COVID-19 grant 1043001 201 0021 (G.V.). Netherlands Organization for Health Research and Development ZonMw & the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group). The Netherlands Organisation for Health Research and Development ZonMW VENI grant, grant number 09150161910033 (L.A.V.V.). Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic [H2020-SC1-PHE-CORONAVIRUS-2020 grant agreement ID: 101003608 ] (M.W.). Semper Ardens Carlsberg Foundation (M.W.). This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the United States Department of Health and Human Services or its components. Conceptualization: G.V. M.W. C.E.v.d.S. A.V. and D.E.S. Methodology: G.V. M.W. J.V.C. T.P. and T.S. Formal analysis: J.V.C. T.P. T.S. and S.K. Investigation: J.V.C. T.S. T.P. S.K. M.S. F.L. R.V. W.W. and J.N. Resources: D.S. L.A.v.V. W.H. M.A.S. R.M. M.K.B. J.J.S. A.S. D.S. M.A.N. B.G.M. R.R. M.L.G. and the UMC COVID-19 S3/HCW study group, Fatebenefratelli-Sacco Infectious Diseases Physicians group and Radboud University Medical Center (RUMC) & Bavarian Nordic (BN) A/S. Data curation: J.V.C. T.S. T.P. S.K. and M.S. Writing – Original draft: G.V. M.W. J.V.C. T.P. and R.R. Writing – Review and editing: J.V.C. T.P. T.S. W.W. J.N. M.L.G. S.K. F.L. O.C. J.B.D.K. R.V. L.A.v.V. M.A.S. N.v.M. M.J.S. A.S. D.E.S. M.S. T.R. M.A.N. B.G.N. A.P.J.V. C.E.v.d.S. R.R. M.W. and G.V. Visualization: T.P. and J.V.C. Supervision: G.V. M.W. A.V. and R.R. Project administration: G.V. M.W. and M.S. Funding acquisition: G.V. M.W. T.P. and Radboud University Medical Center (RUMC) & COUGH1. M.L.G. and R.R. are employees of Janssen Pharmaceuticals and M.L.G. is a shareholder in Johnson & Johnson. A.S. and W.A.d.J. are employees at AdaptVac, a company commercializing virus-like particle display technology and vaccines, including several patents. A.S. A.S. T.G.T. and M.N. are founders of AdaptVac and listed as coinventors on a patent covering the AP205 CLP vaccine platform technology (WO2016112921 A1) licensed to AdaptVac. Janssen Pharmaceuticals sponsored IgG glycosylation analysis at LUMC. Sanquin provided consultancy services to Janssen Pharmaceuticals during this study. All other authors declare they have no conflicts of interests.
Funding Information:
Funding: Landsteiner foundation for Blood Transfusion Research (LSBR) grants 1721 and 1908 (G.V.). ZonMW COVID-19 grant 1043001 201 0021 (G.V.). Netherlands Organization for Health Research and Development ZonMw & the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group). The Netherlands Organisation for Health Research and Development ZonMW VENI grant, grant number 09150161910033 (L.A.V.V.). Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic [H2020-SC1-PHE-CORONAVIRUS-2020 grant agreement ID: 101003608 ] (M.W.). Semper Ardens Carlsberg Foundation (M.W.). This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the United States Department of Health and Human Services or its components.
Publisher Copyright:
© 2023 The Author(s)
ID: 373870913